Invention Grant
- Patent Title: CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
-
Application No.: US14463689Application Date: 2014-08-20
-
Publication No.: US09637542B2Publication Date: 2017-05-02
- Inventor: Alisa K. Waterman , Nick Mark Devoogdt , Tony Lahoutte , Matthias Schneider , Sanjaya Singh , Cedric Jozef Néotère Ververken
- Applicant: Alisa K. Waterman , Nick Mark Devoogdt , Tony Lahoutte , Matthias Schneider , Sanjaya Singh , Cedric Jozef Néotère Ververken
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Michael P. Morris; Atabak R. Royaee
- Main IPC: A61K51/10
- IPC: A61K51/10 ; C07K16/28 ; A61K49/00 ; A61K49/04 ; A61K49/22 ; G01N33/569
Abstract:
The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.
Public/Granted literature
- US20150056133A1 CX3CR1-TARGETING IMAGING AGENTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF DISEASE Public/Granted day:2015-02-26
Information query
